GlobeNewswire Inc | Sep 9, 2021 08:30AM EDT

September 09, 2021

NESS ZIONA, Israel, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (Nasdaq: SLGL), a dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, today announced that the Company will participate in H.C. Wainwrights 23rd Global Investment Conference.

H.C. Wainwright 23^rd Annual Global Investment Conference(September 13? 15,2021)Format On demand presentation and 1-on-1 meetingsSpeaker: Gilad Mamlok, Chief Financial OfficerDate: September 13-15Time: Presentation available on demand beginning Monday, September 13^th 7 a.m. ETTo Register here; a replay will be archived for 90 days at this link (orListen go to www.sol-gel.com to access within the Investors/Events and Presentations section)

About Sol-Gel Technologies

Sol-Gelis a dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. Sol-Gel leverages its proprietary microencapsulation technology platform for TWYNEO, which is FDA approved for the treatment of acne vulgaris in adults and pediatric patients nine years of age and older; and EPSOLAY, under investigation for the treatment of inflammatory lesions of rosacea with an NDA filed with the FDA and a PDUFA goal date that was set forApril26,2021. Action on the NDA for EPSOLAY has not yet been taken due to the inability of the FDA to conduct a pre-approval inspection of the production site of EPSOLAY as a result of COVID-19 travel restrictions. Both product candidates are exclusively licensed forU.S.commercialization withGalderma.

The Companys pipeline also includes early-stage topical drug candidates SGT-210 (erlotinib gel) under investigation for the treatment ofpalmoplantar keratoderma, SGT-310 (tapinarof cream, 1%) and SGT-510 (roflumilast) under investigation for the treatment ofplaque psoriasis and other dermatologic indications.

For additional information, please visitwww.sol-gel.com.

Contact:

Irina KofflerInvestor relations,LifeSci Advisorsikoffler@lifesciadvisors.com+1-917-734-7387

Sol-Gel TechnologiesGilad MamlokChief Financial Officergilad.mamlok@sol-gel.com